Literature DB >> 25973067

Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors.

Ioan Jung1, Simona Gurzu1, Sabin Turdean1, Diana Ciortea1, Danut Ioan Sahlean1, Mircea Golea1, Tivadar Bara2.   

Abstract

Soft tissue tumors are rare tumors that show a heterogeneous structure; thus far, their molecular behavior has not been elucidated. The aim of our study was to define the relationship between microvessel density (MVD), evaluated with CD31, and other immunohistochemical markers, such as vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), CD34, maspin, DOG-1, and c-KIT. Immunostains were done in 55 cases consisting of benign and malignant tumors, such as liposarcomas, dermatofibrosarcomas, and tumors with histiocytic differentiation. Renal tubes were used as external control for VEGF, maspin, and DOG-1. Although DOG-1 is considered a specific marker for gastrointestinal tumors (GISTs), its positivity, correlated with c-KIT and VEGF immunoexpression, was also shown by dermatofibrosarcomas and tumors with histiocytic and lipomatous differentiation, suggesting its possible pro-angiogenic role. Maspin expression was observed in adipose tissue tumors only. Regarding angiogenesis, 31 of the 55 cases were VEGF-positive, such positivity being directly correlated with COX-2 and CD34 positivity as evaluated in the tumor cells and also with MVD. Although no significant differences in angiogenic activity were found between benign and malignant non-lipomatous tumors, the MVD was directly correlated with the histological type/grade of liposarcomas. Based on these aspects, we conclude that VEGF/COX-2-induced angiogenesis is specific for non-lipomatous tumors, whereas liposarcomas are dependent on the VEGF/maspin angiogenic pathway. The DOG-1/c-KIT/VEGF target may be used for further personalized therapy of soft tissue sarcomas. No data about DOG-1 and maspin positivity in liposarcomas have been published to date.

Entities:  

Keywords:  COX-2; DOG-1; Soft tissue; angiogenesis; c-KIT; maspin

Mesh:

Substances:

Year:  2015        PMID: 25973067      PMCID: PMC4396343     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Assessment of angiogenesis in soft-tissue tumors.

Authors:  Virginia Baneth; M Raica; Anca Maria Cîmpean
Journal:  Rom J Morphol Embryol       Date:  2005       Impact factor: 1.033

2.  Study of malignant fibrous histiocytoma: clinical, statistic and histopatological interrelation.

Authors:  D D Pobirci; Fl Bogdan; Oana Pobirci; Carmen Adina Petcu; Elena Roşca
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

3.  Discovered on gastrointestinal stromal tumor 1 (DOG1) is expressed in pancreatic centroacinar cells and in solid-pseudopapillary neoplasms--novel evidence for a histogenetic relationship.

Authors:  Frank Bergmann; Mindaugas Andrulis; Werner Hartwig; Roland Penzel; Matthias M Gaida; Esther Herpel; Peter Schirmacher; Gunhild Mechtersheimer
Journal:  Hum Pathol       Date:  2011-02-04       Impact factor: 3.466

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

5.  DOG1 immunoreactivity in uterine leiomyosarcomas.

Authors:  Shatrughan P Sah; W Glenn McCluggage
Journal:  J Clin Pathol       Date:  2012-10-04       Impact factor: 3.411

6.  Differential clinical and pathological characteristics of esophageal stromal tumors and leiomyomata.

Authors:  B-Y Fei; J-M Yang; Z-S Zhao
Journal:  Dis Esophagus       Date:  2013-02-05       Impact factor: 3.429

7.  Pancreatic expression of DOG1: a novel gastrointestinal stromal tumor (GIST) biomarker.

Authors:  Carmen Ardeleanu; Dorel Arsene; Mihai Hinescu; Florin Andrei; Daniela Gutu; Lacramioara Luca; Laurentiu M Popescu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-10

8.  Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms.

Authors:  Jessica Hemminger; O Hans Iwenofu
Journal:  Histopathology       Date:  2012-05-09       Impact factor: 5.087

9.  The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Authors:  Thomas K Kilvaer; Eivind Smeland; Andrej Valkov; Sveinung W Sorbye; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  BMC Clin Pathol       Date:  2014-01-20

10.  Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma.

Authors:  Thin Thin Win; Hasnan Jaafar; Yusri Yusuf
Journal:  South Asian J Cancer       Date:  2014-07
View more
  5 in total

1.  PKCθ utility in diagnosing c-KIT/DOG-1 double negative gastrointestinal stromal tumors.

Authors:  Attila Kövecsi; Ioan Jung; Zoltan Szentirmay; Tivadar Bara; Tivadar Bara; Daniel Popa; Simona Gurzu
Journal:  Oncotarget       Date:  2017-07-08

2.  Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma.

Authors:  Hongzeng Wu; Qianqian Zhang; Yi Zhao; Fengzhou Xu; Jinming Zhang; Hongyan He; Xu Wang; Helin Feng
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 3.  Chloride Channels and Transporters: Roles beyond Classical Cellular Homeostatic pH or Ion Balance in Cancers.

Authors:  Hyeong Jae Kim; Peter Chang-Whan Lee; Jeong Hee Hong
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

4.  Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer.

Authors:  Nan-Nan Li; Xian-Sheng Meng; Yong-Rui Bao; Shuai Wang; Tian-Jiao Li
Journal:  Pharmacogn Mag       Date:  2018-04-10       Impact factor: 1.085

5.  Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.

Authors:  Feng Li; Zhichao Liao; Jun Zhao; Gang Zhao; Xubin Li; Xiaoling Du; Yun Yang; Jilong Yang
Journal:  Oncotarget       Date:  2017-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.